Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. https://static01.nyt.com/images/2025/04/10/multimedia/00HS-COMPOUNDED-WEIGHTLOSS-01-wbjm/00HS-COMPOUNDED-WEIGHTLOSS-01-wbjm-mediumSquareAt3X.jpg